Bruker (NASDAQ:BRKR) Shares Up 9.2% – Time to Buy?

Bruker Corporation (NASDAQ:BRKR)’s share price traded up 9.2% during trading on Thursday . The company traded as high as $53.22 and last traded at $53.1010. 1,276,187 shares were traded during mid-day trading, a decline of 45% from the average session volume of 2,308,142 shares. The stock had previously closed at $48.62.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Stifel Nicolaus set a $45.00 price target on Bruker in a research note on Friday, May 8th. Guggenheim reduced their price objective on Bruker from $58.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Citigroup raised their price objective on Bruker from $40.00 to $44.00 and gave the stock a “neutral” rating in a research note on Thursday, May 7th. TD Cowen raised their price objective on Bruker from $43.00 to $45.00 and gave the stock a “hold” rating in a research note on Thursday, May 7th. Finally, The Goldman Sachs Group reduced their price objective on Bruker from $40.00 to $35.00 and set a “sell” rating for the company in a research note on Friday, February 13th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Bruker has a consensus rating of “Hold” and an average target price of $50.54.

Bruker Stock Performance

The stock has a market capitalization of $8.13 billion, a PE ratio of -222.42, a PEG ratio of 2.81 and a beta of 1.12. The company has a quick ratio of 0.72, a current ratio of 1.55 and a debt-to-equity ratio of 0.67. The firm has a 50 day moving average price of $39.23 and a 200-day moving average price of $42.63.

Bruker (NASDAQ:BRKR) last posted its earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.23 by $0.08. The firm had revenue of $823.40 million for the quarter, compared to analyst estimates of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.Bruker’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period last year, the company earned $0.47 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Research analysts expect that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 7th. Investors of record on Monday, June 22nd will be issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, June 22nd. Bruker’s dividend payout ratio (DPR) is -83.33%.

Insider Buying and Selling

In related news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total transaction of $79,800.00. Following the sale, the vice president directly owned 128,443 shares of the company’s stock, valued at $5,124,875.70. This trade represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 27.20% of the stock is currently owned by company insiders.

Institutional Trading of Bruker

Several hedge funds and other institutional investors have recently bought and sold shares of BRKR. Los Angeles Capital Management LLC acquired a new stake in Bruker in the fourth quarter valued at approximately $26,000. Parallel Advisors LLC increased its position in shares of Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after buying an additional 479 shares in the last quarter. Allworth Financial LP increased its position in shares of Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after buying an additional 257 shares in the last quarter. Essential Partners LLC purchased a new stake in shares of Bruker in the first quarter valued at approximately $36,000. Finally, Summit Securities Group LLC purchased a new stake in shares of Bruker in the fourth quarter valued at approximately $50,000. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.